These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39016337)

  • 1. Impact of a High-Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor.
    Cardona P; Dutta S; Houk B
    Clin Pharmacol Drug Dev; 2024 Nov; 13(11):1219-1226. PubMed ID: 39016337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS
    Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
    N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
    Hochmair MJ; Vermaelen K; Mountzios G; Carcereny E; Dooms C; Lee SH; Morocz E; Kato T; Ciuleanu TE; Dy GK; Parente B; O'Byrne KJ; Chu QS; Castro Junior G; Girard N; Snyder W; Tran Q; Kormany W; Houk B; Mehta B; Curioni-Fontecedro A
    Eur J Cancer; 2024 Sep; 208():114204. PubMed ID: 39029295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
    Chen M; Huang Y; Jiang S; Ke C
    Lung Cancer; 2024 Oct; 196():107966. PubMed ID: 39342769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food on the bioavailability of palbociclib.
    Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
    Rioux N; Kim A; Nix D; Bowser T; Warmuth M; Smith PG; Schindler J
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):91-96. PubMed ID: 30368584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of food on the pharmacokinetics of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Niland K; Haluska F; Sonnichsen D
    J Clin Pharm Ther; 2013 Dec; 38(6):440-4. PubMed ID: 23888935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
    Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib.
    Cardona P; Dutta S; Houk B
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):810-818. PubMed ID: 38421129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotorasib for Lung Cancers with
    Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
    N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
    Shaik N; Hee B; Wei H; LaBadie RR
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
    Sikes C; Stark JG; McMahen R; Engelking D
    Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
    Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.
    Winter H; Ginsberg A; Egizi E; Erondu N; Whitney K; Pauli E; Everitt D
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5516-20. PubMed ID: 23979737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
    Dean E; Banerji U; Schellens JHM; Krebs MG; Jimenez B; van Brummelen E; Bailey C; Casson E; Cripps D; Cullberg M; Evans S; Foxley A; Lindemann J; Rugman P; Taylor N; Turner G; Yates J; Lawrence P
    Cancer Chemother Pharmacol; 2018 May; 81(5):873-883. PubMed ID: 29541803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.